Skip to main content
. 2023 Dec 13;25(4):207–215. doi: 10.1016/j.ccrj.2023.10.008

Table 2.

Ventilator free days (primary clinical effectiveness outcome) and composite fidelity score (primary implementation outcome) detectable differences.

Ventilator free days (VFDs) (Primary Clinical Effectiveness Outcome)
Cohort Population Baseline mean VFDs SD Total # of measurements ICC Power (%) Detectable Difference in mean VFDs
All MV patients Primary 21 10 18816 0.15 90 0.9
Sustained HRF patients Subgroup 15 11 4928 0.02 90 2.1
ARDS definition 1 patients Subgroup 15 11 4032 0.02 90 2.3
ARDS definition 2 patients Subgroup 15 10 1792 0.02 90 3.0
Sustained ARDS (Calgary)
Subgroup
11
10
2688
0.01
90
2.4
Composite Fidelity Score (CFS) (Primary Implementation Outcome)

Cohort
Population
Baseline mean CFS (%)
SD
Total # of measurements
ICC
Power (%)
Detectable Difference in mean CFS (%)
All MV patients Primary 20 32 18816 0.31 90 2.6
Sustained HRF patients Subgroup 35 29 4928 0.32 90 4.6
ARDS definition 1 patients Subgroup 36 30 4032 0.33 90 5.2
ARDS definition 2 patients Subgroup 38 30 1792 0.38 90 7.4
Sustained ARDS (Calgary) Subgroup 56 29 2688 0.02 90 7.1

ARDS = acute respiratory distress syndrome. CFS = composite fidelity score. ICC = intraclass correlation coefficient. HRF = hypoxemic respiratory failure. MV = mechanically ventilated. SD = standard deviation. VFDs = ventilator free days. Calculations for all MV patients, sustained HRF patients, ARDS definition 1 patients, and ARDS definition 2 patients are based on eCritical registry data from November 2018 to November 2019. Calculations for the ARDS Calgary cohort is based on standardized screening for ARDS in four ICUs in Calgary. See Appendix S2, SAP Supplementary Table 1 for details on criteria for sustained HRF, ARDS definition 1 and 2, and sustained ARDS.